SARS-CoV-2-reactive tissue-resident memory T cells in healthy and cancer subjects
健康和癌症受试者中的 SARS-CoV-2 反应性组织驻留记忆 T 细胞
基本信息
- 批准号:10688355
- 负责人:
- 金额:$ 73.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAddressAnimal ModelAntibodiesAntibody ResponseApoptoticAutomobile DrivingB-LymphocytesBioinformaticsBiological AssayBloodCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCOVID-19COVID-19 pandemicCOVID-19 patientCancer PatientCancer Research ProjectCellsCellular ImmunityClinicalCollaborationsCytomegalovirusDNA VirusesDiseaseEconomicsFrequenciesFruitFutureGenerationsGenomicsHead CancerHuman Herpesvirus 4Human PapillomavirusImmuneImmunityImmunologyIndividualInfectionInflammatoryInfluenzaLarynxLinkMalignant NeoplasmsMalignant neoplasm of lungMeasuresMemoryMorbidity - disease rateMucous MembraneNF-kappa BNatureNeck CancerNoseOncogenic VirusesOperative Surgical ProceduresOropharyngealOutcomePathway interactionsPatientsPeptidesPeripheral Blood Mononuclear CellPropertyRNA VirusesReportingResearch Project GrantsRespiratory SystemSARS-CoV-2 infectionScienceSerologySignal TransductionSiteSpecimenStructure of parenchyma of lungT cell receptor repertoire sequencingT cell responseT memory cellT-LymphocyteTimeTissuesTranscriptTumor TissueVaccinesViralVirusVirus Diseasesanti-PD1 therapyanti-tumor immune responseantigen-specific T cellsbasecancer cellcancer typecellular targetingcohortcross reactivitycytotoxicityexhaustexperiencehuman coronavirusinsightmortalitymouse modelmucosal sitenovel therapeuticspandemic diseasepatient subsetspost SARS-CoV-2 infectionrecruitrespiratoryresponsesevere COVID-19single-cell RNA sequencingtranscriptometranscriptomicstumortumor immunology
项目摘要
PROJECT SUMMARY
This multi-PI proposal titled “SARS-CoV-2-reactive
subjects” is written in response to ‘RFA-CA-20-039’ -
tissue-resident memory T cells in healthy and cancer
Research projects in SARS-CoV-2 Serological Sciences.
Recent studies have shown that antibody responses to SARS-CoV-2 infection decline rapidly over time, implying
a lack of durable protective humoral (B cell) immunity. Whether this is also true for cellular immunity (e.g., T
cells) is poorly understood. It is well established that CD8+ TRM cells are the first line of defense in viral infections
at mucosal/barrier sites. They are also known to protect hosts against homologous or heterologous re-infections.
Our group was the first to show that TRM cells are pivotal players in driving effective anti-tumor immune responses
in lung cancer, and that TRM cells are the primary cellular targets of anti-PD1 therapies. These key findings were
possible because of the ongoing collaboration between Dr. Vijayanand, Dr. Ay, and Dr. Ottensmeier (Multi-PI).
This team brings together experience in T cell immunology, single-cell genomics, bioinformatics, and cancer
immunology. Our Multi-PI team has recently performed the first and largest single-cell RNA-seq and TCR-seq
analysis of SARS-CoV-2-reactive CD8+ and CD4+ T cells (~300,000 single-cells) from COVID-19 patients. Here,
to understand TRM responses to SARS-CoV-2, we will capitalize on a cohort of cancer (n=100) and non-cancer
(n=100) patients, who will provide excess airway (nasal, oropharynx, larynx), lung and tumor tissue specimens
obtained during routine surgery. In AIM 1, we will define the properties of SARS-CoV-2 reactive TRM cells from
cancer and non-cancer patients with or without previous SARS-CoV-2 infection. We will perform combined
single-cell RNA-seq and TCR-seq analysis of CD8+ TRM cells in the airways (nasal, oropharynx), lung, and tumor
tissue. In parallel, by stimulating PBMCs with SARS-CoV-2 peptide pool, we will determine the transcriptomic
and TCR sequence of SARS-CoV-2 reactive T cells. We will utilize this TCR sequence information to define the
numbers and properties of SARS-CoV-2 reactive-TRM cells in mucosal and tumor tissues. Recent studies in non-
exposed individuals (pre-COVID-19 pandemic) indicate pre-existing, circulating CD8+ T cells, with human
coronavirus cross-reactivity. Here, we will measure the quantity and quality of pre-existing SARS-CoV-2 cross-
reactive TRM responses in subjects without clinical or serological evidence of previous SARS-CoV-2 infection. In
AIM 2, we will assess the impact of SARS-CoV-2 infection on anti-tumor and other anti-viral TRM responses. We
will stimulate matched PBMCs (as above) with peptide pools targeting (i) common respiratory RNA viruses
(influenza (FLU), RSV), (ii) persistent DNA viruses (CMV, EBV), and (iii) a tumor-driving virus (HPV) to define
the TCR sequence of the respective virus-specific and tumor(HPV)-specific CD8+ T cells; we will utilize the TCR
information to determine frequency and properties of other virus/tumor-reactive TRM cells in mucosal and tumor-
tissue cells.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ferhat Ay其他文献
Ferhat Ay的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ferhat Ay', 18)}}的其他基金
Using Common Fund datasets for prioritization of disease-associated genetic variants
使用共同基金数据集对与疾病相关的遗传变异进行优先排序
- 批准号:
10585864 - 财政年份:2022
- 资助金额:
$ 73.24万 - 项目类别:
SARS-CoV-2-reactive tissue-resident memory T cells in healthy and cancer subjects
健康和癌症受试者中的 SARS-CoV-2 反应性组织驻留记忆 T 细胞
- 批准号:
10222422 - 财政年份:2020
- 资助金额:
$ 73.24万 - 项目类别:
SARS-CoV-2-reactive tissue-resident memory T cells in healthy and cancer subjects
健康和癌症受试者中的 SARS-CoV-2 反应性组织驻留记忆 T 细胞
- 批准号:
10855009 - 财政年份:2020
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
9980439 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
9576241 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Studying the function of human genetic variation in the light of 3D genome organization
根据 3D 基因组组织研究人类遗传变异的功能
- 批准号:
10624054 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
10603644 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
9751340 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
10226063 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
Defining interaction quantitative trait loci (iQTLs) in the human genome
定义人类基因组中的相互作用数量性状位点 (iQTL)
- 批准号:
10457906 - 财政年份:2018
- 资助金额:
$ 73.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 73.24万 - 项目类别:
Research Grant














{{item.name}}会员




